Join Class Action Lawsuit Against UroGen Pharma Ltd. (URGN) by July 28, 2025

A class-action lawsuit has been filed against UroGen Pharma Ltd. (URGN), with a deadline for joining set for July 28, 2025. The lawsuit was announced by Levi & Korsinsky, a law firm specializing in such cases. The lawsuit claims that UroGen Pharma Ltd. made false and misleading statements that caused the company’s stock price to be artificially inflated. Investors who purchased UroGen Pharma Ltd. stock between January 4, 2022, and June 11, 2025, are eligible to join the class-action lawsuit.

The lawsuit alleges that UroGen Pharma Ltd. failed to disclose important information to investors, which led to the stock being traded at artificially high prices. This includes information about the supposed effectiveness of its key product, UGN-102, in treating low-grade upper tract urothelial cancer. The company’s statements about the drug’s success were allegedly misleading and inflated, leading investors to purchase stock at prices that did not reflect the true value of the company.

Investors who suffered financial losses as a result of purchasing UroGen Pharma Ltd. stock during the specified period may be eligible to join the class-action lawsuit and seek damages. Levi & Korsinsky, the law firm handling the case, is encouraging affected investors to contact them before the July 28th deadline to ensure their participation in the lawsuit.

Class-action lawsuits like this are important tools for investors to seek justice and hold companies accountable for their actions. By coming together as a group, investors can pool their resources and legal expertise to pursue claims against companies that have engaged in fraudulent or deceptive practices. These lawsuits help to protect investors’ rights and recover financial losses caused by misleading or false information provided by companies.

It is important for investors who believe they have been affected by UroGen Pharma Ltd.’s actions to consult with legal counsel to determine their eligibility to join the class-action lawsuit. By participating in the lawsuit, investors may be able to recover some or all of the financial losses they suffered as a result of purchasing UroGen Pharma Ltd. stock during the specified period.

In conclusion, the class-action lawsuit filed against UroGen Pharma Ltd. presents an opportunity for affected investors to seek justice and potentially recover financial losses caused by the company’s alleged misleading statements. By contacting Levi & Korsinsky before the July 28th deadline, investors can ensure their participation in the lawsuit and work towards holding UroGen Pharma Ltd. accountable for its actions.